83 related articles for article (PubMed ID: 16910582)
1. Bisphosphonate and low-dose dexamethasone treatment for patients with hormone-refractory prostate cancer.
Ueda T; Suzuki H; Akakura K; Ishihara M; Kamiya N; Komiya A; Shimbo M; Suyama T; Sakamoto S; Ichikawa T
Hinyokika Kiyo; 2006 Jul; 52(7):515-21. PubMed ID: 16910582
[TBL] [Abstract][Full Text] [Related]
2. Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels.
Kawashima H; Tanaka T; Kuratsukuri K; Uchida J; Sugimura K; Tamada S; Nishisaka N; Kumata K; Iwai Y; Ikemoto S; Ezaki K; Nakatani T
Urol Int; 2007; 78(4):345-50. PubMed ID: 17495494
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
4. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy.
Vogel CL; Yanagihara RH; Wood AJ; Schnell FM; Henderson C; Kaplan BH; Purdy MH; Orlowski R; Decker JL; Lacerna L; Hohneker JA
Oncologist; 2004; 9(6):687-95. PubMed ID: 15561812
[TBL] [Abstract][Full Text] [Related]
5. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.
Petrioli R; Fiaschi AI; Francini E; Pascucci A; Francini G
Cancer Treat Rev; 2008 Dec; 34(8):710-8. PubMed ID: 18620815
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases.
Rosenthal MA; Davidson P; Rolland F; Campone M; Xue L; Han TH; Mehta A; Berd Y; He W; Lombardi A
Asia Pac J Clin Oncol; 2010 Mar; 6(1):42-8. PubMed ID: 20398037
[TBL] [Abstract][Full Text] [Related]
7. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.
Leeming DJ; Hegele A; Byrjalsen I; Hofmann R; Qvist P; Karsdal MA; Schrader AJ; Wagner R; Olbert P
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1269-76. PubMed ID: 18483350
[TBL] [Abstract][Full Text] [Related]
8. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
Xie W; Nakabayashi M; Regan MM; Oh WK
Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
[TBL] [Abstract][Full Text] [Related]
9. Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients.
Rodrigues P; Hering F; Campagnari JC
Prostate Cancer Prostatic Dis; 2004; 7(4):350-4. PubMed ID: 15534620
[TBL] [Abstract][Full Text] [Related]
10. Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria.
Banu E; Banu A; Medioni J; Levy E; Thiounn N; Mejean A; Andrieu JM; Oudard S
Prostate; 2007 Oct; 67(14):1543-9. PubMed ID: 17705243
[TBL] [Abstract][Full Text] [Related]
11. Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer.
Azuma H; Sakamoto T; Kiyama S; Ubai T; Kotake Y; Inamoto T; Takahara K; Nishimura Y; Segawa N; Katsuoka Y
Am J Clin Oncol; 2008 Apr; 31(2):188-94. PubMed ID: 18391605
[TBL] [Abstract][Full Text] [Related]
12. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Thall PF; Logothetis C; Pagliaro LC; Wen S; Brown MA; Williams D; Millikan RE
J Natl Cancer Inst; 2007 Nov; 99(21):1613-22. PubMed ID: 17971530
[TBL] [Abstract][Full Text] [Related]
13. [The effects of clodronate for the pain treatment of bone metastasis due to prostate cancer].
Ozyuvaci E; Altan A; Demir C
Agri; 2005 Jan; 17(1):49-53. PubMed ID: 15791501
[TBL] [Abstract][Full Text] [Related]
14. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
15. Management of the spectrum of hormone refractory prostate cancer.
Clarke NW
Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
[TBL] [Abstract][Full Text] [Related]
16. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
[TBL] [Abstract][Full Text] [Related]
17. Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer.
Mitsiades CS; Bogdanos J; Karamanolakis D; Milathianakis C; Dimopoulos T; Koutsilieris M
Anticancer Res; 2006; 26(5B):3693-700. PubMed ID: 17094387
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease.
Berruti A; Tucci M; Mosca A; Tarabuzzi R; Gorzegno G; Terrone C; Vana F; Lamanna G; Tampellini M; Porpiglia F; Angeli A; Scarpa RM; Dogliotti L
Br J Cancer; 2005 Sep; 93(6):633-8. PubMed ID: 16222309
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of quality of life of patients with hormone-refractory prostate cancer after gene therapy.
Terao S; Shirakawa T; Acharya B; Miyata M; Hinata N; Tanaka K; Takenaka A; Hara I; Naoe M; Fuji K; Okegawa T; Higashihara E; Kamidono S; Fujisawa M; Gotoh A
Anticancer Res; 2009 May; 29(5):1533-7. PubMed ID: 19443362
[TBL] [Abstract][Full Text] [Related]
20. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Amato RJ; Hernandez-McClain J; Henary H
Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]